[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341778-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341778-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","antigen-presenting-cells-in-cancer-immunity-and-mediation-of-immune-checkpoint-blockade-review","Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade - review","","Antigen-presenting cells (APCs) act as central mediators of immune responses, with a growing impact on cancer immunology. Evidence indicates that their functions in cancer immunity depend on surface markers, growth factors, transcription factors, and local context. Key dendritic cell subsets in tumors include cDC1/cDC2, monocyte-derived DCs, plasmacytoid DCs, and mature/regulatory DCs, alongside monocyte–macrophage continua from pro-inflammatory M1 to anti-inflammatory M2 states. This review synthesizes recent findings on DCs, monocytes, and macrophages and analyzes how subset features and signaling pathways shape responses to immune checkpoint blockade (ICB), while identifying knowledge gaps and informing alternative or combination therapeutic strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/antigen-presenting-cells-in-cancer-immunity-and-mediation-of-immune-checkpoint-blockade-review/341778/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/antigen-presenting-cells-in-cancer-immunity-and-mediation-of-immune-checkpoint-blockade-review/341778.png","ImageObject",300,407,{"name":42,"@type":43},"Levi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are antigen-presenting cells important in cancer immunity?","Question",{"text":63,"@type":64},"Antigen-presenting cells (APCs) mediate immune responses and are increasingly implicated in cancer immunology. Their roles depend on multiple biological features and the tumor microenvironment.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which dendritic cell subsets are described in cancers?",{"text":68,"@type":64},"The text highlights conventional DCs (cDC1 and cDC2), monocyte-derived DCs (moDC), plasmacytoid DCs (pDC), and mature/regulatory DCs (mregDC).",{"name":70,"@type":61,"acceptedAnswer":71},"How might myeloid cell characteristics influence response to immune checkpoint blockade?",{"text":72,"@type":64},"The document reviews how abundance, surface markers, and indirect or direct signaling pathways of dendritic cells and macrophages may affect tumor response to immune checkpoint blockade therapy, while noting remaining knowledge gaps.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341778,1790472610,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Clinical & Experimental Metastasis (2024) 41:333–349 [https://doi.org/10.1007/s10585-023-10257-z](https://doi.org/10.1007/s10585-023-10257-z)  \nAntigen presenting cells in cancer immunity and mediation of immune checkpoint blockade  \nCassia Wang1,2 · Lee Chen1 · Doris Fu1,2 · Wendi Liu3 · Anusha Puri4 · Manolis Kellis1,2 · JiekunYang1,2  \nReceived: 2 June 2023 / Accepted: 6 December 2023 / Published online: 23 January 2024 © The Author(s) 2024  \nAbstract  \nAntigen-presenting cells (APCs) are pivotal mediators of immune responses. Their role has increasingly been spotlighted in the realm of cancer immunology, particularly as our understanding of immunotherapy continues to evolve and improve. There is growing evidence that these cells play a non-trivial role in cancer immunity and have roles dependent on surface markers, growth factors, transcription factors, and their surrounding environment. The main dendritic cell (DC) subsets found in cancer are conventional DCs (cDC1 and cDC2), monocyte-derived DCs (moDC), plasmacytoid DCs (pDC), and mature and regulatory DCs (mregDC) . The notable subsets of monocytes and macrophages include classical and non-classical monocytes, macrophages, which demonstrate a continuum from a pro-inflammatory (M1) phenotype to an anti-inflammatory (M2) phenotype, and tumor-associated macrophages (TAMs) . Despite their classification in the same cell type, each subset may take on an immune-activating or immunosuppressive phenotype, shaped by factors in the tumor microenvironment (TME) . In this review, we introduce the role of DCs, monocytes, and macrophages and recent studies investigating them in the cancer immunity context. Additionally, we review how certain characteristics such as abundance, surface markers, and indirect or direct signaling pathways of DCs and macrophages may influence tumor response to immune checkpoint blockade (ICB) therapy. We also highlight existing knowledge gaps regarding the precise contributions of different myeloid cell subsets in influencing the response to ICB therapy. These findings provide a summary of our current understanding of myeloid cells in mediating cancer immunity and ICB and offer insight into alternative or combination therapies that may enhance the success of ICB in cancers.  \nKeywords Cancer immunity · Immune checkpoint blockade · Antigen presenting cells · Dendritic cell · Monocyte · Macrophage  \n\n| Presented at the 9th International Congress on Cancer Metastasis through the Lymphovascular System, May 4–6, 2023, in San Francisco, CA. To be published in a Special Issue of Clinical and Experimental Metastasis: Molecular Mechanisms of Cancer Metastasis. |\n| --- |\n| Cassia Wang and Lee Chen have contributed equally. |\n\n* Jiekun Yang [jkyang@mit.edu](jkyang@mit.edu)  \n1 Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA  \n2 Broad Institute of MIT and Harvard, Cambridge, MA, USA  \n3 Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA  \n4 Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA  \nIntroduction to myeloid cells  \nMyeloid cells are present in immunological settings, where they circulate through the blood and lymphatic system and are recruited to sites of tissue damage and infection [1] . In the tumor microenvironment (TME), myeloid cells can either be immune-activating and/or suppressing. Efforts have been made to target suppressive myeloid cells in cancer, such as tumor-associated macrophages (TAMs), polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) from the neutrophil lineage, mononuclear myeloid-derived suppressor cells (M-MDSCs) from the monocyte lineage, and a combination of myeloid cells [2] . However, research in the role of myeloid cells in cancer, particularly cancer immunity, was generally lacking compared to lymphoid cells. Recently, there has been a heightened focus on myeloid cells due","cbCaihWJepeJ6e2i","https://ap.wps.com/l/cbCaihWJepeJ6e2i","pdf",1681610,17,"English","# Abstract\n# Introduction to myeloid cells\n## Antigen presentation by dendritic cells\n## Activation, maturation, and migration\n## Ontogeny and developmental origins","[{\"question\":\"Why are antigen-presenting cells important in cancer immunity?\",\"answer\":\"Antigen-presenting cells (APCs) mediate immune responses and are increasingly implicated in cancer immunology. Their roles depend on multiple biological features and the tumor microenvironment.\"},{\"question\":\"Which dendritic cell subsets are described in cancers?\",\"answer\":\"The text highlights conventional DCs (cDC1 and cDC2), monocyte-derived DCs (moDC), plasmacytoid DCs (pDC), and mature/regulatory DCs (mregDC).\"},{\"question\":\"How might myeloid cell characteristics influence response to immune checkpoint blockade?\",\"answer\":\"The document reviews how abundance, surface markers, and indirect or direct signaling pathways of dendritic cells and macrophages may affect tumor response to immune checkpoint blockade therapy, while noting remaining knowledge gaps.\"}]","Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade - review | PDF",1790043777,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5926e3e4a9787daf1522a0e0968dc193.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ece64cfeba880d82445b8fa6ac39d1f7.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c4b9c71ca371695d55aa2f184c78025.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d23dc58a606b53db1ab9bd0a5a2bf8ec.webp",980,1301]